查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1363243

吸入器市場規模、佔有率和趨勢分析報告：按藥物類別、用途、地區和細分市場預測，2023-2030 年

Inhalable Drugs Market Size, Share & Trends Analysis Report By Drug Class (Aerosol, Dry Powder Formulation, Spray), By Application (Respiratory & Non-Respiratory Diseases), By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 80 Pages | 商品交期: 2-10個工作天內

價格

吸入器市場成長與趨勢：

Grand View Research, Inc.最新報告顯示，預計到2030年，全球吸入藥物市場規模將超過524億美元，2023年至2030年年複合成長率為6.6%。

呼吸系統疾病患病的上升和老年人口的增加是預計推動市場發展的一些關鍵因素。慢性阻塞性肺病（COPD）是一種危及生命的呼吸系統疾病，預計將成為全球第三大死因。這增加了對吸入藥物的需求。

根據全球疾病負擔研究，2016 年全球報告了 2.51 億個慢性阻塞性肺病病例。因此，開發新型吸入藥物的需求日益增加。例如，2019年1月，維羅納製藥公司獲得世界衛生組織核准開發用於慢性阻塞性肺病適應症的恩西芬汀，並完成了第二期臨床試驗。

吸入藥物的進步預計將推動吸入藥物市場的發展。正在研究奈米顆粒以開發先進的吸入藥物。例如，2019年4月，昆士蘭科技大學的科學家利用負載肺癌吸入粉末的殼聚醣奈米顆粒進行了一項研究。這些奈米顆粒可以輕鬆穿透下呼吸道並擴散到血液中。

糖尿病和帕金森氏症等非呼吸系統疾病患病的上升預計也將推動市場的發展。因此，製造商正在開發創新的、具有成本效益的吸入藥物。例如，2019 年 1 月，MannKind Corporation 為糖尿病患者開發了 Afrezza 並將其商業化。

強大的管道藥物的存在被認為是推動市場成長的關鍵因素之一。全球整體有超過220個項目正在進行臨床試驗。例如，葛蘭素史克的氣喘治療藥物糠酸氟替卡松/維蘭特羅/Umeclidinium Bromide三重聯合治療正處於III階段，很可能在預測期內推出。

公司正在採取聯盟、併購、合作夥伴關係和意識計劃等策略性舉措，以擴大產品系列在市場上獲得更牢固的立足點。例如，2019年7月，Cipla, Inc.與總部位於上海的江蘇創諾藥業成立了一家合資企業，在中華人民共和國成立一家生產呼吸產品的公司。

吸入藥物市場報告亮點

  • 按產品，乾粉製劑憑藉其低密度、易在吸入器中分散等優勢，將在2022年佔據吸入藥物市場的主導地位。
  • 從用途來看，由於氣喘和慢性阻塞性肺病的高患病，呼吸系統疾病在 2022 年的收益中佔據最大的市場佔有率。由於各種神經系統疾病的治療機會較多，非呼吸系統疾病領域正在快速成長。
  • 受成熟的製藥業、醫療保健設施以及吸入器使用意識不斷增強的推動，北美將在 2022 年佔據全球吸入器市場的主導地位。預計亞太市場將在預測期內出現最快的成長。
  • 該行業的主要企業包括阿斯特捷利康、Vectura、西普拉、葛蘭素史克、諾華、萌蒂製藥、勃林格殷格翰國際和邁蘭。

目錄

第1章 調查方法和範圍

第2章 執行摘要

第3章 吸入藥物市場變因、趨勢、範圍

  • 市場體系預測
    • 母市場預測
    • 相關/附隨市場預測
  • 普及和成長預測圖
  • 市場動態
    • 市場促進因素分析
    • 市場抑制因素分析
  • 吸入器市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章 吸入藥物：藥物類別的估計和趨勢分析

  • 吸入器市場：要點
  • 吸入藥物市場：2022 年和 2030 年趨勢和市場佔有率分析
  • 氣霧劑
  • 乾粉配方
  • 噴

第5章 吸入器：用途估算與趨勢分析

  • 吸入器市場：要點
  • 吸入藥物市場：2022 年和 2030 年趨勢和市場佔有率分析
  • 呼吸系統疾病
  • 非呼吸系統疾病

第6章 吸入器市場：區域估計與趨勢分析

  • 區域預測
  • 按地區分類的吸入器市場：重點
  • 北美洲
    • 2018-2030 年市場估計與預測
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 泰國
    • 韓國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭形勢

  • 主要市場參與企業的最新趨勢和影響分析
  • 市場參與企業分類
    • AstraZeneca
    • Sanofi
    • Vectura Group Ltd
    • Viatris Inc.
    • GSK plc.
    • Mundipharma International.
    • Boehringer Ingelheim International GmbH.
    • Cipla Inc.
Product Code: GVR-3-68038-767-4

Inhalable Drugs Market Growth & Trends:

The global inhalable drugs market size is expected to reach over USD 52.4 billion by 2030, according to a new report by Grand View Research, Inc.., registering a CAGR of 6.6% from 2023 to 2030. Rising prevalence of respiratory diseases and increasing geriatric population are some of the key factors expected to drive the market. Chronic obstructive pulmonary disease (COPD) is a life-threatening respiratory ailments, which is projected to become the third leading cause of death globally. This will increase the demand for inhalable drugs.

According to the Global Burden of Disease study, in 2016, 251 million cases of COPD were reported worldwide. Hence, the need for developing new inhalable drugs has increased. For instance, in January 2019, Verona Pharma received WHO approval for developing Ensifentrine indicated for COPD, which has completed Phase II of clinical trials.

Advancements in inhalable drugs is anticipated to propel the inhalable drugsmarket. Nanoparticles are studied for the development of advanced inhalation drugs. For instance, in April 2019, a scientist from Queensland University of Technology conducted a research using chitosan nanoparticles loaded with inhalation powder for lung cancer. These nanoparticles can easily penetrate the lower respiratory tract and can diffuse into the bloodstream.

Rising prevalence of non-respiratory diseases such as diabetes and Parkinson's diseases is also expected to drive the market. Therefore, manufacturers are developing cost-effective and innovative inhalable drugs. For instance, in January 2019, MannKind Corporation developed and commercialized Afrezza for diabetic patients.

Presence of strong pipeline drugs is considered to be one of the major factors estimated to boost the market growth. There are more than 220 ongoing projects under clinical trials globally. For instance, GlaxoSmithKline's triple combination therapy of Fluticasone Furoate/Vilanterol/Umeclidinium Bromide to treat asthma is in Phase III and is likely to be launched during the forecast period.

Companies are undergoing strategic initiatives such as collaborations, mergers and acquisitions, partnerships, and awareness programs to widen their product portfolio and gain a stronger foothold in the market. For instance, in July 2019, Cipla, Inc. entered into a joint venture with Shanghai-based Jiangsu Acebright Pharmaceuticals to establish a company in the People's Republic of China to manufacture respiratory products.

Inhalable Drugs Market Report Highlights:

  • By product, the dry powder formulation segment dominated the market for inhalable drugs in 2022 owing to benefits such as low density and ability to disperse easily through inhalers
  • Based on application, respiratory diseases held the largest market share in terms of revenue in 2022, due to high prevalence of asthma and COPD. The non-respiratory diseases segment is growing at a rapid pace owing to the high opportunity in management of various neurological disorders
  • North America held the leading position in the global inhalable drugs market for inhalable drugs in 2022, driven by established pharmaceutical industry and healthcare facilities and growing awareness about the use of inhalers. The Asia Pacific market is projected to exhibit the fastest growth during the forecast period.
  • Key players in this industry include AstraZeneca; Vectura, Cipla Inc.; GlaxoSmithKline; Novartis; Mundipharma; Boehringer Ingelheim International GmbH; and Mylan.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Drug Class
    • 1.1.2. Application
    • 1.1.3. Regional scope
    • 1.1.4. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Drug class outlook
    • 2.2.2. Application outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Inhalable Drugs Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. Inhalable Drugs Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic landscape

Chapter 4. Inhalable Drugs: Drug Class Estimates & Trend Analysis

  • 4.1. Inhalable Drugs Market: Key Takeaways
  • 4.2. Inhalable Drugs Market: Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Aerosol
    • 4.3.1. Aerosol market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4. Dry Powder Formulation
    • 4.4.1. Dry powder formulation market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. Spray
    • 4.5.1. Spray market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Inhalable Drugs: Application Estimates & Trend Analysis

  • 5.1. Inhalable Drugs Market: Key Takeaways
  • 5.2. Inhalable Drugs Market: Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Respiratory Diseases
    • 5.3.1. Respiratory diseases market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4. Non-respiratory Diseases
    • 5.4.1. Non-respiratory diseases market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Inhalable Drugs Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Outlook
  • 6.2. Inhalable Drugs Market by Region: Key Takeaways
  • 6.3. North America
    • 6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.2. U.S.
      • 6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.3. Canada
      • 6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.2. Germany
      • 6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.3. France
      • 6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.4. Italy
      • 6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.5. Spain
      • 6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.6. Denmark
      • 6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.7. Sweden
      • 6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.8. Norway
      • 6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.2. China
      • 6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.3. India
      • 6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.4. Australia
      • 6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.5. Thailand
      • 6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.6. South Korea
      • 6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.2. Mexico
      • 6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.3. Argentina
      • 6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.7. MEA
    • 6.7.1. South Africa
      • 6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.2. Saudi Arabia
      • 6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.3. UAE
      • 6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.4. Kuwait
      • 6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Market Participant Categorization
    • 7.2.1. AstraZeneca
      • 7.2.1.1. Company overview
      • 7.2.1.2. Financial performance
      • 7.2.1.3. Product benchmarking
      • 7.2.1.4. Strategic initiatives
    • 7.2.2. Sanofi
      • 7.2.2.1. Company overview
      • 7.2.2.2. Financial performance
      • 7.2.2.3. Product benchmarking
      • 7.2.2.4. Strategic initiatives
    • 7.2.3. Vectura Group Ltd
      • 7.2.3.1. Company overview
      • 7.2.3.2. Financial performance
      • 7.2.3.3. Product benchmarking
      • 7.2.3.4. Strategic initiatives
    • 7.2.4. Viatris Inc.
      • 7.2.4.1. Company overview
      • 7.2.4.2. Financial performance
      • 7.2.4.3. Product benchmarking
      • 7.2.4.4. Strategic initiatives
    • 7.2.5. GSK plc.
      • 7.2.5.1. Company overview
      • 7.2.5.2. Financial performance
      • 7.2.5.3. Product benchmarking
      • 7.2.5.4. Strategic initiatives
    • 7.2.6. Mundipharma International.
      • 7.2.6.1. Company overview
      • 7.2.6.2. Financial performance
      • 7.2.6.3. Product benchmarking
      • 7.2.6.4. Strategic initiatives
    • 7.2.7. Boehringer Ingelheim International GmbH.
      • 7.2.7.1. Company overview
      • 7.2.7.2. Financial performance
      • 7.2.7.3. Product benchmarking
      • 7.2.7.4. Strategic initiatives
    • 7.2.8. Cipla Inc.
      • 7.2.8.1. Company overview
      • 7.2.8.2. Financial performance
      • 7.2.8.3. Product benchmarking
      • 7.2.8.4. Strategic initiatives

List of Tables

  • Table 1 List of Abbreviation
  • Table 2 North America inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 3 North America inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 4 North America inhalable drugs market, by region, 2018 - 2030 (USD Million)
  • Table 5 U.S. inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 6 U.S. inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 7 Canada inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 8 Canada inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 9 Europe inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 10 Europe inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 11 Europe inhalable drugs market, by region, 2018 - 2030 (USD Million)
  • Table 12 Germany inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 13 Germany inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 14 UK inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 15 UK inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 16 France inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 17 France inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 18 Italy inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 19 Italy inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 20 Spain inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 21 Spain inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 22 Denmark inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 23 Denmark inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 24 Sweden inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 25 Sweden inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 26 Norway inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 27 Norway inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 28 Asia Pacific inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 29 Asia Pacific inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific inhalable drugs market, by region, 2018 - 2030 (USD Million)
  • Table 31 Japan inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 32 Japan inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 33 China inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 34 China inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 35 India inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 36 India inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 37 Australia inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 38 Australia inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 39 Thailand inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 40 Thailand inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 41 South Korea inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 42 South Korea inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 43 Latin America inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 44 Latin America inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 45 Latin America inhalable drugs market, by region, 2018 - 2030 (USD Million)
  • Table 46 Brazil inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 47 Brazil inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 48 Mexico inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 49 Mexico inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 50 Argentina inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 51 Argentina inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 52 Middle East and Africa inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 53 Middle East and Africa inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 54 Middle East and Africa inhalable drugs market, by region, 2018 - 2030 (USD Million)
  • Table 55 South Africa inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 56 South Africa inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 57 Saudi Arabia inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 58 Saudi Arabia inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 59 UAE inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 60 UAE inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 61 Kuwait inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 62 Kuwait inhalable drugs market, by Application, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Inhalable drugs: Market outlook
  • Fig. 9 Inhalable drugs: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Inhalable drugs market driver impact
  • Fig. 15 Inhalable drugs market restraint impact
  • Fig. 16 Inhalable drugs market strategic initiatives analysis
  • Fig. 17 Inhalable drugs market: Drug class movement analysis
  • Fig. 18 Inhalable drugs market: Drug class outlook and key takeaways
  • Fig. 19 Aerosol market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Dry powder formulation market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Spray market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Inhalable drugs market: Application movement analysis
  • Fig. 23 Inhalable drugs market: Application outlook and key takeaways
  • Fig. 24 Respiratory diseases market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Non-respiratory diseases market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Global inhalable drugs market: Regional movement analysis
  • Fig. 27 Global inhalable drugs market: Regional outlook and key takeaways
  • Fig. 28 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Middle East and Africa. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)